Paydirt
RR
Insider

Robin Shane Readnour

Director

Robin Shane Readnour (Director) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in AN2 Therapeutics, Inc. (ANTX). The largest single filing was $213K of ANTX (35,402 sh across 2 lots, as filed), executed Aug 17.

Add to watchlist
Return, ttmiAverage return per filing, trailing twelve months
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
returns measure stock purchases only
Filings, ttm
1
0 buys · 1 sells
Median delay
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$213K
shares × price, as filed
Last traded
Aug 17
Filed Aug 19

Median ADV $1.7M across their filed names

Open performance
Volume by month
$213K$106K$0Oct 2024Apr 2025Oct 2025Apr 2026Aug 2026 · sells $213K
Buys $0 Sells $213K

Shares × price, as filed · by filing month · past 24 months

Sectors filed on
Healthcare 1 filing

Sector per market data · by filing · past 12 months

Most traded names
ANTX AN2 Therapeutics, Inc. ANTX · 0 buys · 1 sell 1 filing
Recent filings
ANTXSALE AN2 Therapeutics, Inc. View filing → $213K
35,402 sh across 2 lots
Exec Aug 17
Filed Aug 19 · 5:58 PM ET